News

BGB-3111 is the company’s investigational, oral, highly selective and potent inhibitor of BTK, a critical component of B-cell receptor (BCR) signaling that plays a major role in B-cell

Sickle cell disease (SCD), which is the most common inherited blood disorder in the US, is estimated to affect nearly 100,000 people and the estimated cost of care

The trial will be carried out through the National Cancer Institute at the National Institutes of Health (NIH). The company said that prior studies indicate hetIL-15 expands and

The approval allows for marketing of Opdivo in all 28 member states of the European Union (EU) and it follows an accelerated assessment by the European Medicines Agency’s

The data, to be announced on Saturday 20th June at The 1st Congress of the European Academy of Neurology (EAN), shows an improvement of the Clinical Global Impression

Under the terms of the agreement, in exchange for I.V.S. becoming a wholly-owned subsidiary of OphthaliX, OphthaliX will issue to the sellers and option holders of I.V.S. at

US Oncology Research and Cure Forward will work together to make personalized medicine more accessible and approachable in the community setting, reinforcing the cooperation that exists between physicians

SDC Nutrition said it is building on an existing relationship with former CEO of GNC Brazil, Juan Alonso, to market and distribute its sports nutrition brands in Latin

The company should now provide more information to NICE to make a final decision on the use of idelalisib in combination with rituximab for adults with chronic lymphocytic